AN2 Therapeutics, Inc.
ANTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001880438
In the last 90 days, AN2 Therapeutics, Inc. insiders filed 1 open-market purchase and 5 sales; 66 institutions reported holding it in 13F filings for Q2 2026, worth $119.0M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in AN2 Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 51
- +14 vs. Q3 2023
- Shares held
- 20.4M
- +460.0K (+2.3%) vs. Q3 2023
- Total value
- $417.9M
- +$97.6M (+30.5%) vs. Q3 2023
- New holders
- 16
- 16 more added
- Sold out
- 2
- 10 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ANTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 66 | $119.0M |
| Q1 2026 | 52 | $74.8M |
| Q4 2025 | 38 | $9.88M |
| Q3 2025 | 36 | $10.5M |
| Q2 2025 | 37 | $8.78M |
| Q1 2025 | 38 | $19.5M |
| Q4 2024 | 38 | $20.1M |
| Q3 2024 | 31 | $14.5M |
| Q2 2024 | 45 | $41.7M |
| Q1 2024 | 54 | $60.9M |
| Q4 2023 | 51 | $417.9M |
| Q3 2023 | 37 | $320.3M |
| Q2 2023 | 31 | $99.9M |
| Q1 2023 | 38 | $94.8M |
| Q4 2022 | 36 | $92.9M |
| Q3 2022 | 38 | $165.1M |
| Q2 2022 | 36 | $72.4M |
| Q1 2022 | 18 | $134.1M |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding AN2 Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 5,551,295 | $113.7M | 1.78% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 2,678,209 | $54.9M | 6.09% | 00.0% | Unchanged |
| BVF Inc | 1,563,963 | $32.0M | 0.80% | 00.0% | Unchanged |
| Citadel Advisors LLC | 1,556,842 | $31.9M | 0.03% | +2900.0% | Added |
| Frazier Life Sciences Management, L.P. | 1,388,889 | $28.5M | 1.52% | 00.0% | Unchanged |
| Janus Henderson Group PLC | 1,279,975 | $26.3M | 0.02% | −108,975−7.8% | Reduced |
| Avidity Partners Management LP | 1,140,000 | $23.4M | 0.89% | +50,600+4.6% | Added |
| Vanguard Group Inc | 1,052,591 | $21.6M | 0.00% | +112,700+12.0% | Added |
| Adage Capital Partners GP, L.L.C. | 900,672 | $18.5M | 0.04% | −4,884−0.5% | Reduced |
| Octagon Capital Advisors LP | 664,575 | $13.6M | 2.18% | −203,000−23.4% | Reduced |
| Marshall Wace, LLP | 337,321 | $6.91M | 0.01% | −379,460−52.9% | Reduced |
| BlackRock Inc. | 305,841 | $6.27M | 0.00% | +263,679+625.4% | Added |
| Nantahala Capital Management, LLC | 248,278 | $5.09M | 0.51% | −108,511−30.4% | Reduced |
| Price T Rowe Associates Inc | 187,399 | $3.84M | 0.00% | +187,399 | New |
| Geode Capital Management, LLC | 178,623 | $3.66M | 0.00% | +88,932+99.2% | Added |
| Citigroup Inc | 160,486 | $3.29M | 0.00% | +1,381+0.9% | Added |
| Invesco Ltd. | 157,891 | $3.24M | 0.00% | −30,006−16.0% | Reduced |
| Acuta Capital Partners, LLC | 132,000 | $2.70M | 1.52% | +118,700+892.5% | Added |
| Susquehanna International Group, LLP | 99,404 | $2.04M | 0.00% | +75,141+309.7% | Added |
| Qube Research & Technologies Ltd | 72,208 | $1.48M | 0.00% | +72,208 | New |
| Jane Street Group, LLC | 59,445 | $1.22M | 0.00% | +59,445 | New |
| Victory Capital Management Inc | 51,660 | $1.06M | 0.00% | −440−0.8% | Reduced |
| Alyeska Investment Group, L.P. | 50,000 | $1.02M | 0.01% | 00.0% | Unchanged |
| RMB Capital Management, LLC | 45,942 | $941.4K | 0.03% | 00.0% | Unchanged |
| Barclays PLC | 44,238 | $906.4K | 0.00% | +41,068+1,295.5% | Added |
| Laurion Capital Management LP | 43,814 | $897.7K | 0.03% | +43,814 | New |
| Millennium Management LLC | 39,674 | $812.9K | 0.00% | +39,674 | New |
| Deutsche Bank AG | 39,472 | $808.8K | 0.00% | +39,472 | New |
| State Street Corp | 38,302 | $784.8K | 0.00% | +22,900+148.7% | Added |
| Bridgeway Capital Management, LLC | 36,992 | $758.0K | 0.02% | −10,508−22.1% | Reduced |
| Monashee Investment Management LLC | 33,997 | $696.6K | 0.12% | −65,498−65.8% | Reduced |
| Northern Trust Corp | 33,050 | $677.2K | 0.00% | +16,415+98.7% | Added |
| Captrust Financial Advisors | 28,667 | $587.4K | 0.00% | 00.0% | Unchanged |
| ExodusPoint Capital Management, LP | 25,842 | $530.0K | 0.01% | +25,842 | New |
| TD Asset Management Inc | 25,800 | $528.6K | 0.00% | +25,800 | New |
| Bank of America Corp | 21,894 | $448.6K | 0.00% | +18,799+607.4% | Added |
| Balyasny Asset Management LLC | 19,285 | $395.1K | 0.00% | +19,285 | New |
| Two Sigma Investments, LP | 19,248 | $394.4K | 0.00% | +19,248 | New |
| Man Group plc | 18,337 | $375.7K | 0.00% | +18,337 | New |
| Cubist Systematic Strategies, LLC | 16,483 | $337.7K | 0.00% | +16,483 | New |
| Goldman Sachs Group Inc | 14,046 | $287.8K | 0.00% | +14,046 | New |
| 683 Capital Management, LLC | 13,392 | $274.4K | 0.03% | +13,392 | New |
| Manufacturers Life Insurance Company, The | 9,842 | $201.7K | 0.00% | +9,842 | New |
| Morgan Stanley | 3,331 | $68.3K | 0.00% | +546+19.6% | Added |
| FMR LLC | 670 | $13.7K | 0.00% | 00.0% | Unchanged |
| Point72 Asia (Singapore) Pte. Ltd. | 621 | $12.7K | 0.00% | +621 | New |
| Advisor Group Holdings, Inc. | 300 | $6.15K | 0.00% | +100+50.0% | Added |
| Federated Hermes, Inc. | 258 | $5.29K | 0.00% | +160+163.3% | Added |
| Rhumbline Advisers | 250 | $5.12K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 126 | $2.58K | 0.00% | +64+103.2% | Added |
| Tower Research Capital LLC (TRC) | 63 | $1.29K | 0.00% | −2,982−97.9% | Reduced |
| UBS Group AG | 0 | $0 | 0.00% | −41,046−100.0% | Sold out |
| Heritage Wealth Advisors | 0 | $0 | 0.00% | −1,060−100.0% | Sold out |